retatrutide weight loss study results After 40: Realistic Timelines New Phase 3 retatrutide data

Wu HY, Tang XQ, Mao XF, Wang YX (2017) Autocrine Interleukin-10 mediates Glucagon-Like Peptide-1 receptor-Induced spinal microglial beta-endorphin expression

This can lead to body weight loss

The image below highlights the mechanisms of both GLP-1 and GIP, along with a callout to the newest treatment optiona triple incretin that also includes glucagonexpected to be approved in late 2025 to early 2026

The outcome of this meeting often determines the submission timeline

doi: 10.1007/s10973-009-0288-9

Your job is to make sure that while the medication reduces your appetite, you still give your body the nutrients it needs to stay healthy, strong, and functional - not just lighter